10/079,452 20832Y

Case No.: Page No.:

2

AMENDMENT


Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1(currently amended): A compound having the formula (I):



or a pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic [5-7] 6 membered ring containing 1 [or 2] nitrogen ring atoms or an aza bicyclo octane ring;

HetAr is a 5 or 6 membered heteroaromatic ring containing 1-3 nitrogen ring atoms, or isoxazolyl, thiazolyl, thiadiazolyl, quinolinyl, quinazolinyl, purinyl, pteridinyl, benzimidazolyl, pyrrolopyrimidinyl, or imidazopyridinyl;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-;

Serial No.: 10/079,452 Case No.: 20832Y Page No.: 3

A is -C[[0]] 1-4alkyl-;

B is $aryl(CH_2)_{0.3}$ –O–C(O)–, heteroaryl(CH₂)_{1.3}–O–C(O)–, indanyl(CH₂)_{0.3}–O–C(O)–, aryl(CH₂)_{1.3}–C(O)–, aryl–cyclopropyl–C(O)–, heteroaryl–cyclopropyl–C(O)–, heteroaryl(CH₂)_{1.3}–NH–C(O)–, aryl(CH₂)_{1.3}–NH–C(NCN)–, aryl(CH₂)_{1.3}–SO₂–, heteroaryl(CH₂)_{1.3}–SO₂–, wherein any of the aryl or heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro; and

X is H, OH, F, C₁₋₄alkyl, C₁₋₄alkoxy, NH₂, or X taken with an adjacent bond is =0.

Claim 2(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₀₋₃–O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 3(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 4(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is an isoxazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-,

Page No.: 4

phenylethynyl-, heteroarylethynyl-,- $N(C_{0-4}alkyl)(C_{0-4}alkyl)$, nitro, $(C_{1-2}alkyl)(C_{1-2}alkyl)NCH_{2-}$, $(C_{1-2}alkyl)HNCH_{2-}$, $(C_{1-2}alkyl)HNCH_{2-}$, or $NH_{2}C(O)$ -.

Claim 5(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a thiadiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 6(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 5 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH2—, (C_{1-2} alkyl)HNCH2—, Si(C_{1-2} alkyl)- C_{1-2} alkyl)HNCH2—, Si(C_{1-2} alkyl)- C_{1-2} alkyl)

Claim 7(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 8(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-

Page No.: 5

4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 9(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,- $N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂—, (C_{1-2} alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Claim 10(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is thiazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 11(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2—, (C_1 -2alkyl)HNCH2—, Si(C_1 -3alkyl)-C—, or NH2C(O)—.

Claim 12(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

Serial No.: 10/079,452 Case No.: 20832Y Page No.: 6

HetAr is pyrrolopyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 13(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 14(previously presented): The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁₋₄alkyl, C₁₋₄alkoxy, C₂₋₄alkynyl, trifluoromethyl, hydroxy, hydroxyC₁₋₄alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀₋₄alkyl)(C₀₋₄alkyl), nitro, (C₁₋₂alkyl)(C₁₋₂alkyl)NCH₂-, (C₁₋₂alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 15(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₁₋₃–SO₂–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 16(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms;

Page No.: 7

HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,– $N(C_0$ -4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂–, (C₁-2alkyl)HNCH₂–, Si(CH₃)₃–C–, or NH₂C(O)–.

Claim 17(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is quinazolinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)–.

Claim 18(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,–N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂–, (C₁-2alkyl)HNCH₂–, Si(CH₃)₃–C–, or NH₂C(O)–.

Claim 19(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

HetAr is imidazopyridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 20(previously presented): The compound according to Claim 15, or a pharmaceutically acceptable salt thereof, wherein

Page No.: 8

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)–.

Claim 21(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is a nonaromatic 5 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₀₋₃-O-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 22(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atoms; HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 23(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is pteridinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1} -4alkyl, C_{1} -4alkoxy, C_{2} -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1} -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_{0}$ -4alkyl)(C_{0} -4alkyl), nitro, (C_{1} -2alkyl)(C_{1} -2alkyl)NCH₂—, (C_{1} -2alkyl)HNCH₂—, Si(CH₃)3—C—, or NH₂C(O)—.

Page No.: 9

Claim 24(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—, $-N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, $(C_{1-2}$ alkyl)(C_{1-2} alkyl)NCH2—, $(C_{1-2}$ alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 25(withdrawn): The compound according to Claim 21, or pharmaceutically acceptable salts thereof, wherein

HetAr is benzimidazolyl optionally substituted with 1 or 2 substituents, each substituent independently is C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkynyl, trifluoromethyl, hydroxy, hydroxy C_{1-4} alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,- $N(C_{0-4}$ alkyl)(C_{0-4} alkyl), nitro, (C_{1-2} alkyl)(C_{1-2} alkyl)NCH₂-, (C_{1-2} alkyl)HNCH₂-, Si(C_{1-2} alkyl)HNCH₂-, or NH₂C(O_{1-2}

Claim 26(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is $aryl(CH_2)_{0.3}$ –O–C(O)–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 27(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 1 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Serial No.: Case No.:

Page No.: 10

10/079,452

20832Y

Claim 28(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is purinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C_0 -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH₂-, (C_1 -2alkyl)HNCH₂-, Si(C_1 -3alkyl)-C-, or NH₂C(O_1 -2alkyl)-.

Claim 29(withdrawn): The compound according to Claim 26, or pharmaceutically acceptable salts thereof, wherein

HetAr is a 6 membered heteroaromatic ring containing 2 nitrogen ring atom; and HetAr is optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)–.

Claim 30(withdrawn): The compound according to Claim 1, or pharmaceutically acceptable salts thereof, wherein

NonAr is an aza bicyclo octane ring; and

B is $aryl(CH_2)_{1-3}$ –SO₂–, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 31(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is heteroaryl(CH₂)₁₋₃-C(O)-, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Serial No.: 10/079,452 Case No.: 20832Y Page No.: 11

Claim 32(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₁₋₃-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 33(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl-cyclopropyl-C(O)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁₋₄alkyl, C₃₋₆cycloalkyl, C₁₋₄alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 34(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyridyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)-.

Claim 35(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C_1 -4alkyl, C_1 -4alkoxy, C_2 -4alkynyl, trifluoromethyl, hydroxy, hydroxy C_1 -4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl—, phenylethynyl—, heteroarylethynyl—,— $N(C_0$ -4alkyl)(C_0 -4alkyl), nitro, (C_1 -2alkyl)(C_1 -2alkyl)NCH2—, (C_1 -2alkyl)HNCH2—, Si(CH3)3—C—, or NH2C(O)—.

Claim 36(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

Serial No.: 10/079,452 Case No.: 20832Y Page No.: 12

HetAr is pyridazinyl optionally substituted with 1 or 2 substituents, each substituent independently is C1-4alkyl, C1-4alkoxy, C2-4alkynyl, trifluoromethyl, hydroxy, hydroxyC1-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl-, phenylethynyl-, heteroarylethynyl-,-N(C0-4alkyl)(C0-4alkyl), nitro, (C1-2alkyl)(C1-2alkyl)NCH2-, (C1-2alkyl)HNCH2-, Si(CH3)3-C-, or NH2C(O)-.

Claim 37(previously presented): The compound according to Claim 33, or a pharmaceutically acceptable salt thereof, wherein

HetAr is pyrimidinyl optionally substituted with 1 or 2 substituents, each substituent independently is C₁-4alkyl, C₁-4alkoxy, C₂-4alkynyl, trifluoromethyl, hydroxy, hydroxyC₁-4alkyl, fluoro, chloro, bromo, iodo, cyano, methylsulfanyl, cyclopropylethynyl–, phenylethynyl–, heteroarylethynyl–,-N(C₀-4alkyl)(C₀-4alkyl), nitro, (C₁-2alkyl)(C₁-2alkyl)NCH₂-, (C₁-2alkyl)HNCH₂-, Si(CH₃)₃-C-, or NH₂C(O)–.

Claim 38(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is heteroaryl(CH₂)₁₋₃–O–C(O)–, wherein the heteroaryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro;.

Claim 39(previously presented): The compound according to Claim 1, or a pharmaceutically acceptable salt thereof, wherein

NonAr is a nonaromatic 6 membered ring containing 1 nitrogen ring atom; and B is aryl(CH₂)₁₋₃-NH-C(NCN)-, wherein the aryl is optionally substituted by 1-5 substitutents, each substituent independently is C₁-4alkyl, C₃-6cycloalkyl, C₁-4alkoxy, trifluoromethyl, bromo, fluoro, or chloro.

Claim 40(original): The compound according to Claim 1, wherein said compound is

NOV 1 2 2004

Serial No.:

10/079,452 20832Y 13

- 4			
TOPE	TZ ZZ	NH NH O	
	N NH O		L C C C C C C C C C C C C C C C C C C C
	O N H N N N N N N N N N N N N N N N N N		

10/079,452 20832Y 14

N N N N N N N N N N N N N N N N N N N		NH ₂ N N N N N N N N N N N N N N N N N N N
		N H N N N N N N N N N N N N N N N N N N
F N H N	CI N H N H N H N H N H N H N H N H N H N	

Serial No.: Case No.: Page No.:

10/079,452 20832Y 15

F N N N N N N N N N N N N N N N N N N N		N OH OH
H N OH	CH ₃ OH ZI	OH HN N
O N NC	O N N N CI	O N HN F ₃ C

10/079,452 20832Y 16

HN N	O N H OH	
HO-NH N-O	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	HN NH N-O
F C C N C N N N N N N N N N N N N N N N	OH H	Br NH N
F NH NHO		
CI NH NH O		

10/079,452 20832Y 17

CI Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z		ZH ZH O
H CI CI		
		CI NH NH NH
F N H N O O	CI N H N N N N N N N N N N N N N N N N N	
	N NH NH O	N HN N

Serial No.: Case No.: 10/079,452 20832Y

Page No.:

18

HN N O	NA N	HN N N O
OH OH		

or a pharmaceutically acceptable salt thereof.

Claim 41(original): The compound according to Claim 1, wherein said compound is

	N HN O S S O	
l.		NH
	N—NH—O=	N—NH O = N S S S S S S S S S S S S S S S S S S

10/079,452 20832Y

Case No.: Page No.:

19

CI NH O II NH NH O II	N-NH N-SI	NH OH OH
	F—NH 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	NH 0 = S
ı	N NH O S S S S S S S S S S S S S S S S S S	
	H ₂ N N O ₂ N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N

or a pharmaceutically acceptable salt thereof.

Claim 42(currently amended): A compound is-represented by

The compound according to Claim 1, wherein said

or a pharmaceutically acceptable salt thereof.

10/079,452

Case No.: Page No.:

20832Y 20

Claim 43(currently amended): compound is-represented by

The compound according to Claim 1, wherein said \underline{A}

or a pharmaceutically acceptable salt thereof.

Claim 44(previously presented): The compound according to Claim 1, wherein said compound is

Serial No.: Case No.: 10/079,452 20832Y

Page No.:

21

	HN N N
HN N NH ₂	

Serial No.: Case No.: 10/079,452 20832Y

Page No.:

22

		O N H N N N N N N N N N N N N N N N N N
O N H N N	P N H N N N N N N N N N N N N N N N N N	

or a pharmaceutically acceptable salt thereof.

Claim 45(previously presented): The compound according to Claim 1, wherein said compound is

|--|--|--|

10/079,452 20832Y 23

		F N N N N N N N N N N N N N N N N N N N
F N N F	F N F	F F F
F N N N N F F	F N N N N N N N N N N N N N N N N N N N	N= N- N- N- N- N- N- N-
N N N N N N N N N N N N N N N N N N N	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	

10/079,452 20832Y 24

H Z Z Z	F F N N N N N N N N N N N N N N N N N N	O HN N= Br
HIN—N===\$i-	HN-N-	N-N-N-=N
N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-N-	HN-\N-\N-\N-\N-\N-\N-\N-\N-\N-\N-\N-\N-\N
H N N N N N N N N N N N N N N N N N N N		
H N N F F		
F N N N F		

Serial No.: Case No.: Page No.:

10/079,452 20832Y

25

H N F F	T Z Z Z F	
THE STATE OF THE S		
	Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	
F N N F F F	T Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	F N N N N N N N N N N N N N N N N N N N
N H F	D, Z H	

or a pharmaceutically acceptable salt thereof.

Claim 46(previously presented): The compound according to Claim 1, wherein said compound is

Serial No.: 10/079,452 Case No.: 20832Y Page No.: 26

or a pharmaceutically acceptable salt thereof.

Claim 47(currently amended): A compound is-represented by

The compound according to Claim 1, wherein said

or a pharmaceutically acceptable salt thereof.

Claim 48(original): A pharmaceutical composition comprising an inert carrier and an effective amount of a compound according to claim 1.

Claim 49(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat pain.

Claim 50(previously presented): A pharmaceutical composition comprising an inert carrier and an amount of a compound according to claim 1 effective to treat migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke.

 Serial No.:
 10/079,452

 Case No.:
 20832Y

 Page No.:
 27

Claim 51(original): A method of treating pain comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.

Claim 52(original): A method of treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, or stroke comprising a step of administering to one in need of such treatment an effective amount of a compound according to claim 1.